Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors
This retrospective case series describes the association between ocular hemorrhage and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors (statins). The clinical characteristics of 95 case reports submitted to the World Health Organization (WHO), the Food and Drug Administration,...
Gespeichert in:
| Veröffentlicht in: | Journal of ocular pharmacology and therapeutics 2004-04, Vol.20 (2), p.179-182 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 182 |
|---|---|
| container_issue | 2 |
| container_start_page | 179 |
| container_title | Journal of ocular pharmacology and therapeutics |
| container_volume | 20 |
| creator | FRAUNFELDER, F. W |
| description | This retrospective case series describes the association between ocular hemorrhage and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors (statins). The clinical characteristics of 95 case reports submitted to the World Health Organization (WHO), the Food and Drug Administration, and the National Registry of Drug-Induced Ocular Side Effects are summarized with classification of this ocular side effect according to WHO criteria. The average time to onset of ocular hemorrhage was 300 days with 11 positive dechallenge reports and 2 positive rechallenge cases. Some patients also received medications known to increase bleeding times. From the collected data, ocular hemorrhage is "possibly" due to statin therapy. |
| doi_str_mv | 10.1089/108076804773710858 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1089_108076804773710858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15117574</sourcerecordid><originalsourceid>FETCH-LOGICAL-c244t-eff0300f5a8ae92721cd556603672782951ec7783ab64a672770a23cb024bbd03</originalsourceid><addsrcrecordid>eNplkEtLw0AUhQdRbK3-ARcyG5fRO-9kWUIfQqUbXYeZyYyJpE2ZSRb9905pQcHNfRy-c7kchB4JvBDIi9dUQMkcuFJMpUXkV2hKhFBZEuh1mhOQJYJN0F2M3wCEgSS3aEIEIUooPkWLrR07HXDjdn0Ijf5y-NDH2JruiIfG4eDi2A2493j9vsrKfp6UerSDjg63-6Y17dCHeI9uvO6ie7j0GfpcLj7KdbbZrt7K-SazlPMhc94DA_BC59oVVFFiayGkBCYVVTktBHFWqZxpI7k-aQo0ZdYA5cbUwGaInu_akJ4MzleH0O50OFYEqlMm1f9MkunpbDqMZufqX8slhAQ8XwAdre580Hvbxj-cFJQXnP0AqxJnsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><creator>FRAUNFELDER, F. W</creator><creatorcontrib>FRAUNFELDER, F. W</creatorcontrib><description>This retrospective case series describes the association between ocular hemorrhage and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors (statins). The clinical characteristics of 95 case reports submitted to the World Health Organization (WHO), the Food and Drug Administration, and the National Registry of Drug-Induced Ocular Side Effects are summarized with classification of this ocular side effect according to WHO criteria. The average time to onset of ocular hemorrhage was 300 days with 11 positive dechallenge reports and 2 positive rechallenge cases. Some patients also received medications known to increase bleeding times. From the collected data, ocular hemorrhage is "possibly" due to statin therapy.</description><identifier>ISSN: 1080-7683</identifier><identifier>EISSN: 1557-7732</identifier><identifier>DOI: 10.1089/108076804773710858</identifier><identifier>PMID: 15117574</identifier><language>eng</language><publisher>Larchmont, NY: Liebert</publisher><subject>Adverse Drug Reaction Reporting Systems ; Biological and medical sciences ; Drug toxicity and drugs side effects treatment ; Eye Hemorrhage - chemically induced ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Toxicity: eye</subject><ispartof>Journal of ocular pharmacology and therapeutics, 2004-04, Vol.20 (2), p.179-182</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c244t-eff0300f5a8ae92721cd556603672782951ec7783ab64a672770a23cb024bbd03</citedby><cites>FETCH-LOGICAL-c244t-eff0300f5a8ae92721cd556603672782951ec7783ab64a672770a23cb024bbd03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3042,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15652494$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15117574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FRAUNFELDER, F. W</creatorcontrib><title>Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors</title><title>Journal of ocular pharmacology and therapeutics</title><addtitle>J Ocul Pharmacol Ther</addtitle><description>This retrospective case series describes the association between ocular hemorrhage and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors (statins). The clinical characteristics of 95 case reports submitted to the World Health Organization (WHO), the Food and Drug Administration, and the National Registry of Drug-Induced Ocular Side Effects are summarized with classification of this ocular side effect according to WHO criteria. The average time to onset of ocular hemorrhage was 300 days with 11 positive dechallenge reports and 2 positive rechallenge cases. Some patients also received medications known to increase bleeding times. From the collected data, ocular hemorrhage is "possibly" due to statin therapy.</description><subject>Adverse Drug Reaction Reporting Systems</subject><subject>Biological and medical sciences</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Eye Hemorrhage - chemically induced</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Toxicity: eye</subject><issn>1080-7683</issn><issn>1557-7732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkEtLw0AUhQdRbK3-ARcyG5fRO-9kWUIfQqUbXYeZyYyJpE2ZSRb9905pQcHNfRy-c7kchB4JvBDIi9dUQMkcuFJMpUXkV2hKhFBZEuh1mhOQJYJN0F2M3wCEgSS3aEIEIUooPkWLrR07HXDjdn0Ijf5y-NDH2JruiIfG4eDi2A2493j9vsrKfp6UerSDjg63-6Y17dCHeI9uvO6ie7j0GfpcLj7KdbbZrt7K-SazlPMhc94DA_BC59oVVFFiayGkBCYVVTktBHFWqZxpI7k-aQo0ZdYA5cbUwGaInu_akJ4MzleH0O50OFYEqlMm1f9MkunpbDqMZufqX8slhAQ8XwAdre580Hvbxj-cFJQXnP0AqxJnsQ</recordid><startdate>200404</startdate><enddate>200404</enddate><creator>FRAUNFELDER, F. W</creator><general>Liebert</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200404</creationdate><title>Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors</title><author>FRAUNFELDER, F. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c244t-eff0300f5a8ae92721cd556603672782951ec7783ab64a672770a23cb024bbd03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adverse Drug Reaction Reporting Systems</topic><topic>Biological and medical sciences</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Eye Hemorrhage - chemically induced</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Toxicity: eye</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FRAUNFELDER, F. W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of ocular pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FRAUNFELDER, F. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors</atitle><jtitle>Journal of ocular pharmacology and therapeutics</jtitle><addtitle>J Ocul Pharmacol Ther</addtitle><date>2004-04</date><risdate>2004</risdate><volume>20</volume><issue>2</issue><spage>179</spage><epage>182</epage><pages>179-182</pages><issn>1080-7683</issn><eissn>1557-7732</eissn><abstract>This retrospective case series describes the association between ocular hemorrhage and 3-hydroxy-3-methylglutaryl conenzyme A (HMG-CoA) reductase inhibitors (statins). The clinical characteristics of 95 case reports submitted to the World Health Organization (WHO), the Food and Drug Administration, and the National Registry of Drug-Induced Ocular Side Effects are summarized with classification of this ocular side effect according to WHO criteria. The average time to onset of ocular hemorrhage was 300 days with 11 positive dechallenge reports and 2 positive rechallenge cases. Some patients also received medications known to increase bleeding times. From the collected data, ocular hemorrhage is "possibly" due to statin therapy.</abstract><cop>Larchmont, NY</cop><pub>Liebert</pub><pmid>15117574</pmid><doi>10.1089/108076804773710858</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1080-7683 |
| ispartof | Journal of ocular pharmacology and therapeutics, 2004-04, Vol.20 (2), p.179-182 |
| issn | 1080-7683 1557-7732 |
| language | eng |
| recordid | cdi_crossref_primary_10_1089_108076804773710858 |
| source | Mary Ann Liebert Online Subscription; MEDLINE |
| subjects | Adverse Drug Reaction Reporting Systems Biological and medical sciences Drug toxicity and drugs side effects treatment Eye Hemorrhage - chemically induced Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Male Medical sciences Middle Aged Pharmacology. Drug treatments Toxicity: eye |
| title | Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A09%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ocular%20hemorrhage%20possibly%20the%20result%20of%20HMG-CoA%20reductase%20inhibitors&rft.jtitle=Journal%20of%20ocular%20pharmacology%20and%20therapeutics&rft.au=FRAUNFELDER,%20F.%20W&rft.date=2004-04&rft.volume=20&rft.issue=2&rft.spage=179&rft.epage=182&rft.pages=179-182&rft.issn=1080-7683&rft.eissn=1557-7732&rft_id=info:doi/10.1089/108076804773710858&rft_dat=%3Cpubmed_cross%3E15117574%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15117574&rfr_iscdi=true |